Pfizer
Trade Pfizer 24 hours a day, five days a week on Robinhood.
Robinhood gives you the tools to revolutionize your trading experience. Use the streamlined mobile app, or access advanced charts and execute precise trades on our browser-based platform, Robinhood Legend. Risks and limitations apply.About PFE
Pfizer Inc. is a research-based global biopharmaceutical company, which engages in the discovery, development, manufacture, marketing, sales and distribution of biopharmaceutical products worldwide. The firm works across developed and emerging markets to advance wellness, prevention, treatments and cures that challenge the most feared diseases.
PFE Key Statistics
Stock Snapshot
As of today, Pfizer(PFE) shares are valued at $24.26. The company's market cap stands at 138.41B, with a P/E ratio of 18.15 and a dividend yield of 7.27%.
On 2026-06-26, Pfizer(PFE) stock moved within a range of $23.70 to $24.35. With shares now at $24.26, the stock is trading +2.4% above its intraday low and -0.4% below the session's peak.
Trading activity shows a volume of 58.83M, compared to an average daily volume of 55.98M.
Over the past 52 weeks, Pfizer(PFE) stock has traded between a high of $28.75 and a low of $23.11.
Over the past 52 weeks, Pfizer(PFE) stock has traded between a high of $28.75 and a low of $23.11.
PFE News
Pfizer Inc (PFE) announced an update on their ongoing clinical study. Unlock powerful investing tools and data-driven insights with TipRanks Premium for more c...
...
The U.S. FDA has expanded the label for Pfizer’s IBRANCE to include maintenance treatment for HR+, HER2+ metastatic breast cancer. The decision addresses a har...
Analyst ratings
59%
of 29 ratingsMore PFE News
Key Points AbbVie is aggressively expanding its pipeline to offset the impact of biosimilar competition for its top-selling drugs. Pfizer is utilizing substan...
On Wednesday, the U.S. Food and Drug Administration (FDA) approved Pfizer Inc.’s (NYSE:PFE) Ibrance (palbociclib) regimen for frontline maintenance for metastat...
Pfizer (PFE) announced the U.S. Food and Drug Administration approved Ibrance in combination with trastuzumab, with or without pertuzumab, and endocrine therapy...
The U.S. Food and Drug Administration on Wednesday approved a label expansion for Pfizer’s (PFE) breast cancer therapy, palbociclib, marketed as Ibrance. Accor...
Pfizer Inc (PFE) announced an update on their ongoing clinical study. Unlock powerful investing tools and data-driven insights with TipRanks Premium for more c...
Global data is sending mixed signals on growth, inflation and interest rates, yet one trend cuts through the noise: healthcare is increasingly turning to artifi...
Pfizer stock is showing downward bias. Where is PFE stock headed? What Are the Latest Phase 3 Results for Pfizer? Pfizer also flagged that an exploratory analys...
People also own
Similar Marketcap
This list is generated by looking at the six larger and six smaller companies by market cap in relation to this company.
Popular Stocks
This list is generated by looking at the top 100 stocks and ETFs most commonly held by Robinhood customers and showing a random subset
Newly Listed
This list is generated by showing companies that recently went public.